ADT + Docetaxel Improves Overall Survival in Prostate Cancer
Preliminary results from an NIH-supported clinical trial showed that men with hormone-sensitive metastatic prostate cancer who received docetaxel at the start of standard hormone therapy lived longer than patients who received hormone therapy alone.
E3805 was a randomized controlled clinical trial that enrolled 790 men with metastatic prostate cancer between July 2006 and November 2012. All patients received an initial hormone therapy known as androgen deprivation therapy (ADT). Male patients received either ADT alone or ADT with docetaxel every 3 weeks for 18 weeks.
Early findings showed a significant improvement in the overall survival for patients who received ADT plus docetaxel compared to ADT alone (3-year survival rates of 69.0% vs. 52.5%, respectively).
Patients with a high extent of metastasis accounted for majority of the benefit in the overall survival from ADT plus docetaxel compared to ADT alone (3-year survival rates of 63.4% vs. 43.9%, respectively).
Study investigators noted, however, that the use of docetaxel in combination with ADT should be limited to patients with high-extent metastatic prostate cancer who are candidates for treatment with docetaxel.
There are plans for further follow-up on patients with less extensive metastasis who participated in E3805 in order to define the effect of this treatment combination.
For more information call (800) 422-6237 or visit the National Cancer Institute website.